07:00 , Apr 6, 2015 |  BioCentury  |  Finance

Fundamental rally

2Q15 Financial Markets Preview Following three consecutive years of spectacular returns and a solid first quarter, bankers and buysiders remain confident that large caps will continue to deliver on sales and smaller companies will continue...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

Firdapse amifampridine regulatory update

Catalyst said FDA granted Orphan Drug designation to Firdapse amifampridine to treat congenital myasthenic syndromes. The company plans to submit an NDA to FDA for Firdapse to treat Lambert-Eaton myasthenic syndrome (LEMS) in 3Q15. Firdapse...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Financial News

Catalyst Pharma financial update

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX), Coral Gables, Fla.   Business: Neurology   Date announced: 2015-02-09   Note: Catalyst raised $4.9 million through the sale of 1.5 million shares at $3.25 to cover the overallotment from...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Financial News

Catalyst Pharma completes follow-on

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX), Coral Gables, Fla.   Business: Neurology   Date completed: 2015-02-04   Type: Follow-on   Raised: $32.5 million   Shares: 10 million   Price: $3.25   Shares after offering: 79.1 million...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Company News

Catalyst Pharma management update

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX), Coral Gables, Fla.   Business: Neurology   Promoted: David Muth to EVP and chief commercial officer, a newly created position, from EVP of corporate development  ...
08:00 , Jan 12, 2015 |  BioCentury  |  Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

Firdapse amifampridine: Phase III data

Top-line data from a double-blind, international Phase III trial in 38 patients with LEMS showed that Firdapse met the co-primary endpoints of improving QMG and SGI scores from baseline to day 14 vs. placebo. Patients...
02:30 , Sep 30, 2014 |  BC Extra  |  Clinical News

Catalyst's Firdapse meets in LEMS Phase III

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) said its oral potassium channel blocker Firdapse amifampridine met the co-primary endpoints in a Phase III trial to treat Lambert-Eaton myasthenic syndrome (LEMS). In the 38-patient study, Firdapse improved scores...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Company News

Catalyst Pharma management update

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX), Coral Gables, Fla.   Business: Neurology   Hired: David Muth as EVP of corporate development, a newly created position, formerly president and CEO of the Croma Pharmaceuticals Inc. subsidiary of...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Clinical News

CPP-115: Phase I started

Catalyst began a 2-part, U.S. Phase Ib trial to evaluate single and multiple doses of CPP-115 in up to 38 healthy, male volunteers. The trial will evaluate increases in brain GABA levels, which Catalyst believes...